Electrochemical Measurement of Neurohypophyseal Peptide Levels in Rat Hypothalamic Regions after Adrenalectomy

Johnson, Janel V.; Bennett, Gerald; Marsden, C.A.; Gardiner, Sheila M.; Bennett, T.

doi:10.3109/10641968409046115

Cited by 3 publications

(3 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The observed lower PCR-unadjusted treatment failure on days 28 and 42 in the DHA-PQ treatment arm was similar with that of former reviews from Africa [ 5 , 7 ]. As seen in Myanmar, Papua New Guinea, Angola, and elsewhere in Africa, recurrent parasitaemia due to recrudescence occurs significantly more frequently in those patients treated with AL in the first 28 days [ 21 , 52 – 56 ].…”

Section: Discussionsupporting

confidence: 89%

“…During malaria epidemics, a drug with a longer prophylactic effect might limit presumptuous transmission of malaria. On the contrary, AL has shown a significant reduction in PCR-adjusted treatment failure in Asia and Senegal on days 28 and 42, respectively [ 5 , 21 , 69 ].…”

Section: Discussionmentioning

confidence: 99%

“…The partner drug, with a longer half-life, eliminates the residual parasites over several weeks post-treatment, reducing repeated episodes and onward transmission, especially in high and seasonal transmission areas [ 4 ]. Artemisinin and partner drugs protect each other to prevent resistance development [ 5 – 8 ].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Efficacy of dihydroartemisinin-piperaquine versus artemether-lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria among children in Africa: a systematic review and meta-analysis of randomized control trials

Assefa

Yismaw

Makonnen

2021

Malar J

View full text Add to dashboard Cite

Background Emergence of Plasmodium falciparum resistance to artemisinin and its derivatives poses a threat to the global effort to control malaria. The emergence of anti-malarial resistance has become a great public health challenge and continues to be a leading threat to ongoing malaria control efforts. The aim of this review was to synthesize available evidence on the efficacy of dihydroartemisinin-piperaquine (DHA-PQ) compared to artemether-lumefantrine (AL) for the treatment of uncomplicated falciparum malaria among children in Africa. Methods A systematic literature search was done to identify relevant articles from online databases PubMed/ MEDLINE, Embase, and Cochrane Central Register of Controlled Trials’ database (CENTRAL) for retrieving randomized control trials comparing efficacy of DHA-PQ and AL for treatment of uncomplicated falciparum malaria in African children. The search was performed from August 2020 to April 2021. Using Rev-Man software (V5.4.1), R-studio and Comprehensive Meta-analysis software version 3, the extracted data from eligible studies were pooled as risk ratio (RR) with 95% confidence interval (CI). Results In this review, 25 studies which involved a total of 13,198 participants were included. PCR-unadjusted treatment failure in children aged between 6 months and 15 years was significantly lower in the DHA-PQ treatment arm on day 28 than that of AL (RR 0.14, 95% CI 0.08–0.26; participants = 1302; studies = 4; I2 = 0%, high quality of evidence). Consistently, the PCR-adjusted treatment failure was significantly lower with DHA-PQ treatment group on day 28 (RR 0.45, 95% CI 0.29–0.68; participants = 8508; studies = 16; I2 = 51%, high quality of evidence) and on day 42 (RR 0.60, 95% CI 0.47–0.78; participants = 5959; studies = 17; I2 = 0%, high quality of evidence). However, the efficacy was ≥ 95% in both treatment groups on day 28. Conclusion From this review, it can be concluded that DHA-PQ reduces new infection and recrudescence on days 28 and 42 more than AL. This may trigger DHA-PQ to become a first-line treatment option.

show abstract